Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 2NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Endocrine 1

Conditions

Thyroid Neoplasms 31Thyroid Cancer, Papillary 26Pheochromocytoma 23Adenocarcinoma, Follicular 23Adrenocortical Carcinoma 21Neuroendocrine Tumors 20Carcinoma, Medullary 17Somatostatinoma 14Insulinoma 14Thyroid Carcinoma, Anaplastic 13Pituitary Neoplasms 13Paraganglioma 13Carcinoma, Neuroendocrine 12Glucagonoma 11Carcinoma, Renal Cell 11Parathyroid Neoplasms 10Pancreatic Neoplasms 10Gastrinoma 10Carcinoma, Non-Small-Cell Lung 10Carcinoma, Hepatocellular 10Head and Neck Neoplasms 9Colonic Neoplasms 9Carcinoma, Islet Cell 9Breast Neoplasms 9Small Cell Lung Carcinoma 8Sarcoma 8Neoplasms 8Rectal Neoplasms 7Multiple Endocrine Neoplasia Type 1 7Adrenal Gland Neoplasms 7

Interventions

Sorafenib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Familial medullary thyroid carcinoma × Endocrine × Clear all
NCT00390325 2024-02-06

Sorafenib Tosylate in Treating Patients With Metastatic, Locally Advanced, or Recurrent Medullary Thyroid Cancer

National Cancer Institute (NCI)

Phase 2 Completed
21 enrolled 15 charts
EndocrineHead & Neck

Familial medullary thyroid carcinoma, Carcinoma, Medullary, Multiple Endocrine Neoplasia Type 2a, Multiple Endocrine Neoplasia Type 2b

Data powered by HemOnc (CC BY 4.0) Colophon âš¡